REDWOOD CITY, Calif. – May 24, 2016 – C2 Therapeutics, a privately-held medical device company founded to improve methods of eradicating unwanted tissue in endoscopic applications, today announced new data from four separate clinical studies designed to assess the safety and efficacy of its C2 CryoBalloon™ Focal Ablation System (CbFAS). The data, which support the safety and efficacy of the company’s CbFAS, were presented at Digestive Disease Week (DDW) 2016,which is taking place May 21 – 24 in San Diego.
US ONLY: The Coldplay CryoBalloon™ Ablation System is intended for use as a cryosurgical tool in the field of general surgery, specifically for endoscopic applications, to include ablation of Barrett’s Esophagus with high grade dysplasia.
EU ONLY: The CryoBalloon Focal Ablation System is used to ablate unwanted tissue in the gastrointestinal tract, including treatment of Barrett’s Esophagus and squamous dysplasia, by application of extreme cold.
303 Convention Way
Redwood City, CA 94063